Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 11:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 525 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Obesity or Overweight Clear all
Completed No phase listed Observational

Endotoxin and Intestinal Flora Before and After Gastric Bypass or Banding in Diabetics

NCT00960765
View directory record Official record
Conditions
Obesity, Morbid, Diabetes Mellitus, Type 2, Gastric Bypass
Interventions
Not listed
Lead sponsor
CPL Associates
Other
Eligibility
18 Years to 95 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Buffalo, New York • Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Jun 25, 2026, 11:18 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity

NCT06976372
View directory record Official record
Conditions
Overweight, Obesity
Interventions
AMG 133
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Anaheim, California • Los Alamitos, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Jun 25, 2026, 11:18 PM EDT
Not listed Not applicable Interventional

Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects w/o Type 2 Diabetes

NCT03058029
View directory record Official record
Conditions
Overweight, Diabetes, PreDiabetes, Obesity
Interventions
Gelesis200, Placebo
Device
Lead sponsor
Gelesis, Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
12
States / cities
Birmingham, Alabama • Bradenton, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Jun 25, 2026, 11:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effect of Nutrient Intake on the Microbiome, Weight, and Glucoregulation (NI-MWG)

NCT03076424
View directory record Official record
Conditions
Obesity, Type2 Diabetes
Interventions
no intervention used
Other
Lead sponsor
North Dakota State University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Jun 25, 2026, 11:18 PM EDT
Not yet recruiting Phase 3 Interventional

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

NCT07667803
View directory record Official record
Conditions
Weight Management
Interventions
Elecoglipron, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
4,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
26
States / cities
Birmingham, Alabama • Chandler, Arizona • Lincoln, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jun 25, 2026, 11:18 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06914895
View directory record Official record
Conditions
Type 1 Diabetes, Obesity, Overweight
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
31
States / cities
Santa Barbara, California • Santa Clarita, California • Aurora, Colorado + 27 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jun 25, 2026, 11:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

To Evaluate the Post-Prandial Metabolic Effects of Oligomalt in Adults With T2D and in HAO

NCT05963594
View directory record Official record
Conditions
Dietary Supplement
Interventions
Oligomalt, maltodextrin
Dietary Supplement
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jun 25, 2026, 11:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pain and Acetaminophen in Women Study

NCT04573426
View directory record Official record
Conditions
Overweight, Obesity, Healthy Adults
Interventions
Acetaminophen, Placebo, Weight stigma vignette, Control vignette
Drug · Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Jun 25, 2026, 11:18 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks

NCT00297180
View directory record Official record
Conditions
Obesity
Interventions
GW869682
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
3
States / cities
Daytona Beach, Florida • Baton Rouge, Louisiana • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Jun 25, 2026, 11:18 PM EDT
Recruiting Phase 3 Interventional

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

NCT07253285
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
8 Years to 18 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
34
States / cities
Escondido, California • Hollywood, Florida • Jacksonville, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jun 25, 2026, 11:18 PM EDT
Recruiting Phase 2 Interventional

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

NCT06897475
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
LY3457263, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Santa Ana, California • Ocala, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 25, 2026, 11:18 PM EDT
Completed Not applicable Interventional

Helping Educate and Advance Learning Through Healthy Bite-Sized Eating Strategies

NCT06082830
View directory record Official record
Conditions
Adolescent Obesity, Adolescent Overweight, Diet, Healthy
Interventions
Intervention
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
14 Years to 17 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Jun 25, 2026, 11:18 PM EDT
Completed Not applicable Interventional

Study of Produce Prescription Programs in Adults With Overweight or Obesity Experiencing Nutrition Insecurity

NCT06751563
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Behavioral Text Messages and Produce Box Delivery, Behavioral Text Message Program and Produce Voucher
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jun 25, 2026, 11:18 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity

NCT07476118
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Brenipatide, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jun 25, 2026, 11:18 PM EDT
Recruiting Phase 2 Interventional

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

NCT07215559
View directory record Official record
Conditions
Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions
Macupatide, Eloralintide, Macupatide Placebo, Eloralintide Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
26
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 25, 2026, 11:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation

NCT00388180
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidaemias, Obesity
Interventions
GW501516, GW590735
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 18, 2012 · Synced Jun 25, 2026, 11:18 PM EDT
Recruiting No phase listed Observational

Healthy Living BEYOND Weight Study

NCT07075341
View directory record Official record
Conditions
Overweight or Obesity
Interventions
None - Observational study
Other
Lead sponsor
American Heart Association
Other
Eligibility
18 Years and older
Enrollment
1,000,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2060
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Jun 25, 2026, 11:18 PM EDT
Completed Phase 3 Interventional Results available

STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

NCT03548935
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Overweight or Obesity
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
39
States / cities
Anniston, Alabama • Anaheim, California • Lomita, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Jun 25, 2026, 11:18 PM EDT
Completed Phase 3 Interventional Results available

Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity

NCT02664441
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Exenatide, placebo
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
10 Years to 25 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Minneapolis, Minnesota • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Jun 25, 2026, 11:18 PM EDT
Recruiting Not applicable Interventional

Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss

NCT04228978
View directory record Official record
Conditions
Peripheral Artery Disease, Overweight or Obesity
Interventions
Weight loss, Exercise
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Chicago, Illinois • New Orleans, Louisiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jun 25, 2026, 11:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PHP-303 in Otherwise Healthy Overweight or Obese Subjects

NCT03775278
View directory record Official record
Conditions
Otherwise Healthy Overweight or Obese
Interventions
PHP-303, Placebo
Drug · Other
Lead sponsor
pH Pharma
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Jun 25, 2026, 11:18 PM EDT
Active, not recruiting Phase 3 Interventional

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

NCT06952530
View directory record Official record
Conditions
Hypertension
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
28
States / cities
Phoenix, Arizona • Covina, California • Northridge, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 25, 2026, 11:18 PM EDT
Completed Phase 1 Interventional

A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or Obesity

NCT06737536
View directory record Official record
Conditions
Overweight, Obesity
Interventions
NNC0662-0419, Placebo (NNC0662-0419)
Drug · Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
19 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jun 25, 2026, 11:18 PM EDT
Not yet recruiting Not applicable Interventional

Reset: Enhancing Weight Loss in a Digital Intervention

NCT07032571
View directory record Official record
Conditions
Obesity, Overweight, Weight Loss, Health Behavior, Lifestyle Intervention
Interventions
Core Behavioral Weight Loss Intervention, Limit Red Zone Foods, Limit Eating Window, Increase Protein, Increase Fiber Intake
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jun 25, 2026, 11:18 PM EDT